pudexacianinium chloride
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Intraoperative Ureter Visualization
Conditions
Intraoperative Ureter Visualization, Abdominolpelvic Surgery
Trial Timeline
Mar 19, 2024 → Oct 13, 2025
NCT ID
NCT05999747About pudexacianinium chloride
pudexacianinium chloride is a phase 3 stage product being developed by Astellas Pharma for Intraoperative Ureter Visualization. The current trial status is completed. This product is registered under clinical trial identifier NCT05999747. Target conditions include Intraoperative Ureter Visualization, Abdominolpelvic Surgery.
What happened to similar drugs?
1 of 2 similar drugs in Intraoperative Ureter Visualization were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05999747 | Phase 3 | Completed |
| NCT05754333 | Phase 3 | Completed |
| NCT05495581 | Phase 1 | Completed |
| NCT05457842 | Phase 2 | Terminated |
| NCT04238481 | Phase 2 | Completed |
Competing Products
3 competing products in Intraoperative Ureter Visualization
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 40 |
| Rocuronium | Merck | Pre-clinical | 26 |
| Floseal | Baxter | Approved | 40 |